Last reviewed · How we verify
Guanfacine (GUA)
Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity.
Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine release in the brain, decreasing sympathetic nervous system activity. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents, Hypertension.
At a glance
| Generic name | Guanfacine (GUA) |
|---|---|
| Sponsor | Children's Hospital Medical Center, Cincinnati |
| Drug class | Alpha-2A adrenergic receptor agonist |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
By selectively binding to alpha-2A adrenergic receptors in the prefrontal cortex and other brain regions, guanfacine decreases norepinephrine signaling, which improves attention, impulse control, and reduces hyperactivity. This mechanism makes it particularly useful for conditions characterized by executive dysfunction and hyperarousal, such as ADHD and hypertension.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents
- Hypertension
Common side effects
- Somnolence
- Fatigue
- Headache
- Dizziness
- Dry mouth
- Hypotension
- Bradycardia
Key clinical trials
- Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
- Guanfacine to Improve Substance Use Outcomes in Women (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |